KSCM
EFTRW

Kamunting Street Capital Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Kamunting Street Capital Management’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,666
Closed -$6K – 47
2022
Q1 		$6K Buy
+16,666
New +$8.48K 0.01% 36

Other funds holding EFTRW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.82% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ECM
Evolution Capital Management Crystal Bay, Nevada $29M AUM 2.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
ICM
III Capital Management Boca Raton, Florida $344M AUM 11.22% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Kamunting Street Capital Management's EFTRW Position: Q2 2022 in Review

Kamunting Street Capital Management sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q2 2022, closing a stake of 16,666 shares — an estimated $6K sold.

Kamunting Street Capital Management first reported a position in EFTRW in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 16 funds tracked by Wall St. Rank hold EFTRW as of Q2 2022.

  • Kamunting Street Capital Management reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q2 2022 after selling out during the quarter.
  • Kamunting Street Capital Management sold 16,666 eFFECTOR Therapeutics, Inc. Warrant shares in Q2 2022, an estimated $6K.
  • Kamunting Street Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2022 and held it in 1 quarter.
  • Kamunting Street Capital Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $6K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q2 2022.

Based on Kamunting Street Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.